Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Optas LLC

Optas LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,740 shares of the medical research company’s stock after selling 320 shares during the quarter. Optas LLC’s holdings in Thermo Fisher Scientific were worth $962,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Summa Corp. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $418,000. Private Wealth Management Group LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $110,000. Brookstone Capital Management lifted its holdings in Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares during the last quarter. Y.D. More Investments Ltd boosted its position in shares of Thermo Fisher Scientific by 33.9% during the 4th quarter. Y.D. More Investments Ltd now owns 391 shares of the medical research company’s stock valued at $207,000 after purchasing an additional 99 shares in the last quarter. Finally, Private Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the 4th quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock worth $45,187,000 after purchasing an additional 815 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. TD Cowen lifted their price target on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. HSBC boosted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Stifel Nicolaus increased their price target on Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Royal Bank of Canada upped their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Stock Up 0.4 %

TMO traded up $2.26 during trading on Friday, reaching $606.12. 777,265 shares of the stock traded hands, compared to its average volume of 1,530,541. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $622.30. The stock’s 50-day simple moving average is $574.15 and its two-hundred day simple moving average is $573.81. The stock has a market cap of $231.37 billion, a price-to-earnings ratio of 38.88, a price-to-earnings-growth ratio of 2.81 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $5.15 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The disclosure for this sale can be found here. Insiders have sold 33,084 shares of company stock valued at $19,767,092 over the last three months. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.